Skip to main navigation
  • News & Investors

    News & Investors

    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact
  • Contact Us
Celsion
  • TECHNOLOGY
    • LTSL
    • TheraPlas
    • TheraSilence
  • PRODUCTS
    • ThermoDox
    • GEN-1
  • PIPELINE
    • Clinical Studies
    • Pre-clinical Programs
  • DISEASES
  • PUBLICATIONS
  • ABOUT US
    • Leadership
    • Board of Directors
    • Corporate Governance
Select Page

10-Q

    Investor Relations

    • News & Investors
    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact

SEC Filing Details

Document Details

Form
10-Q
Filing Date
Nov 14, 2018
Document Date
Sep 30, 2018
Form Description
Quarterly report which provides a continuing view of a company's financial position
Filing Group
Quarterly Filings
Company
Celsion Corporation
Issuer
CELSION CORP

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.INS - XBRL INSTANCE FILE
EX-101.SCH - XBRL SCHEMA FILE
EX-101.CAL - XBRL CALCULATION FILE
EX-101.DEF - XBRL DEFINITION FILE
EX-101.LAB - XBRL LABEL FILE
EX-101.PRE - XBRL PRESENTATION FILE

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • Downloads
    • RSS
    • Print
    • Search

    • Facebook
    • Google
    • LinkedIn
    • Twitter
    • RSS

Home

Technology

Products

Pipeline

Disease

Publications

News & Investors

About Us

Careers

Privacy Policy

    ThermoDox is a registered trademark of Celsion Corporation.
    TheraPlas and TheraSilence are trademarks of Celsion Corporation.
    Avastin is a registered trademark of Genentech, Inc.
    Copyright © 2021 Celsion Corporation. All rights reserved.

    Share This
    • Twitter
    • Google+
    • Facebook
    • LinkedIn